Amgen’s supplemental Biologics License Application for Xgeva for the prevention of skeletal-related events in multiple myeloma patients has been approved by the US FDA.
The approval is based on data from the pivotal Phase 3 ‘482 study, the largest international multiple myeloma clinical trial ever conducted, which enrolled 1,718 patients.
“Up to 40% of patients remain untreated for the prevention of bone complications, and the percentage is highest among patients with renal impairment at the time of diagnosis,” said Noopur Raje, Director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston.
“Denosumab (Xgeva), which is not cleared through the kidneys, offers multiple myeloma patients bone protection with a convenient subcutaneous administration, providing patients with a novel treatment option.”
Xgeva is a fully human monoclonal antibody that binds to and neutralizes RANK ligand (RANKL) – a protein essential for the formation, function and survival of osteoclasts, which break down bone – thereby inhibiting osteoclast-mediated bone destruction.
It is currently the number one prescribed bone-targeting agent in the US for the prevention of skeletal-related events in patients with bone metastases from solid tumours.
Additional regulatory applications for the prevention of skeletal-related events in patients with multiple myeloma are underway and have been submitted to health authorities worldwide.